AlloVir Inc. (ALVR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALVR Stock Price Chart Interactive Chart >
ALVR Price/Volume Stats
| Current price | $5.78 | 52-week high | $10.29 |
| Prev. close | $5.65 | 52-week low | $3.17 |
| Day low | $5.67 | Volume | 192,328 |
| Day high | $5.91 | Avg. volume | 228,141 |
| 50-day MA | $6.13 | Dividend yield | N/A |
| 200-day MA | $6.16 | Market Cap | 538.48M |
AlloVir Inc. (ALVR) Company Bio
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.
Latest ALVR News From Around the Web
Below are the latest news stories about ALLOVIR INC that investors may wish to consider to help them evaluate ALVR as an investment opportunity.
AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should KnowAlloVir, Inc. (ALVR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8%The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 355.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year. |
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023WALTHAM, Mass., January 09, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced the company’s 2023 priorities and anticipated future milestones across its pipeline of virus-specific T cell therapies, including its lead investigational therapy posoleucel. These updates will be the focus of a corporate presentation by Chief Executive Officer Diana Brainard, M.D., at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January |
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., January 03, 2023--AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2023, at 2:15 p.m. PST. |
ALVR Price Returns
| 1-mo | 12.67% |
| 3-mo | -17.78% |
| 6-mo | -11.35% |
| 1-year | -29.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 12.67% |
| 2022 | -60.36% |
| 2021 | -66.34% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...